ADC Therapeutics (ADCT) Net Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted Net Margin of 158.11% for Q1 2026, up 36.6% sequentially from 249.38% in Q3 2025, and up 948.0% YoY from 15.09% in Q1 2025.
ADC Therapeutics (ADCT) Net Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Net Margin for 6 years, with the latest figure at 158.11% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -86.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.06% |
| Mar 31, 2026 | -158.11% |
| Sep 30, 2025 | -249.38% |
| Jun 30, 2025 | -300.68% |
| Mar 31, 2025 | -167.59% |
| Sep 30, 2024 | -236.73% |
| Jun 30, 2024 | -206.47% |
| Mar 31, 2024 | -254.81% |
| Sep 30, 2023 | -312.58% |
| Jun 30, 2023 | -249.96% |
| Mar 31, 2023 | -312.90% |
| Sep 30, 2022 | -66.31% |
| Jun 30, 2022 | -372.30% |
| Mar 31, 2022 | -35.83% |
| Sep 30, 2021 | -544.22% |
| Jun 30, 2021 | -1,930.03% |